PathAI, Inc. is a Boston-based AI technology company founded in 2016, specializing in precision pathology solutions. The company develops AI models and digital pathology platforms to optimize the analysis of patient tissue samples, enhancing diagnostic accuracy and supporting drug development.
Key offerings include AISight, a cloud-native image management system for digital pathology workflows, and over 20 AI algorithms such as PathExplore and PathAssist Derm, trained on more than 32.5 million annotations from a network of over 450 pathologists. PathAI serves biopharma firms for biomarker discovery, clinical trials, and translational research, as well as pathology labs and clinicians.
In May 2026, Roche announced a definitive agreement to acquire PathAI for an upfront $750 million plus up to $300 million in milestones, with closure expected in the second half of 2026, subject to approvals. Upon completion, PathAI will integrate into Roche's Diagnostics division.
